The Experts below are selected from a list of 4737 Experts worldwide ranked by ideXlab platform
Paul Y Liu - One of the best experts on this subject based on the ideXlab platform.
-
basic fgf or vegf gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons
Scientific Reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation and (3) significantly increased tendon strength by 68–91% from week 2 after AAV2-bFGF treatment and by 82–210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after Healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the Intrinsic Healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.
-
Basic FGF or VEGF gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons.
Scientific reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p
Xiao Tian Wang - One of the best experts on this subject based on the ideXlab platform.
-
basic fgf or vegf gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons
Scientific Reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation and (3) significantly increased tendon strength by 68–91% from week 2 after AAV2-bFGF treatment and by 82–210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after Healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the Intrinsic Healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.
-
Basic FGF or VEGF gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons.
Scientific reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p
Jin Bo Tang - One of the best experts on this subject based on the ideXlab platform.
-
basic fgf or vegf gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons
Scientific Reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation and (3) significantly increased tendon strength by 68–91% from week 2 after AAV2-bFGF treatment and by 82–210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after Healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the Intrinsic Healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.
-
Basic FGF or VEGF gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons.
Scientific reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p
Yi Cao - One of the best experts on this subject based on the ideXlab platform.
-
basic fgf or vegf gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons
Scientific Reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation and (3) significantly increased tendon strength by 68–91% from week 2 after AAV2-bFGF treatment and by 82–210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after Healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the Intrinsic Healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.
-
Basic FGF or VEGF gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons.
Scientific reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p
Chuan Hao Chen - One of the best experts on this subject based on the ideXlab platform.
-
basic fgf or vegf gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons
Scientific Reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p < 0.05 or p < 0.01), (2) significantly promoted production of type I collagen and other extracellular molecules (p < 0.01) and accelerated cellular proliferation and (3) significantly increased tendon strength by 68–91% from week 2 after AAV2-bFGF treatment and by 82–210% from week 3 after AAV2-VEGF compared with that of the controls (p < 0.05 or p < 0.01). Moreover, the transgene expression dissipated after Healing was complete. These findings show that the gene transfers provide an optimistic solution to the insufficiencies of the Intrinsic Healing capacity of the tendon and offers an effective therapeutic possibility for patients with tendon disunion.
-
Basic FGF or VEGF gene therapy corrects insufficiency in the Intrinsic Healing capacity of tendons.
Scientific reports, 2016Co-Authors: Jin Bo Tang, Yi Cao, Chuan Hao Chen, You Lang Zhou, Bella Avanessian, Masaru Shimada, Xiao Tian Wang, Paul Y LiuAbstract:Tendon injury during limb motion is common. Damaged tendons heal poorly and frequently undergo unpredictable ruptures or impaired motion due to insufficient innate Healing capacity. By basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) gene therapy via adeno-associated viral type-2 (AAV2) vector to produce supernormal amount of bFGF or VEGF Intrinsically in the tendon, we effectively corrected the insufficiency of the tendon Healing capacity. This therapeutic approach (1) resulted in substantial amelioration of the low growth factor activity with significant increases in bFGF or VEGF from weeks 4 to 6 in the treated tendons (p
